Trial Profile
Claims-linked Survey Study to Assess Burden of Illness Among Patients Treated With LAMA/LABA vs ICS/LABA Single Inhaler Dual Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 27 Sep 2019 Status changed from recruiting to completed.
- 15 Aug 2019 Planned End Date changed from 30 Aug 2019 to 20 Sep 2019.